170 related articles for article (PubMed ID: 8137289)
1. Effect of 9-benzyl-9-deazaguanine, a potent inhibitor of purine nucleoside phosphorylase, on the cytotoxicity and metabolism of 6-thio-2'-deoxyguanosine.
Parker WB; Allan PW; Niwas S; Montgomery JA; Bennett LL
Cancer Res; 1994 Apr; 54(7):1742-5. PubMed ID: 8137289
[TBL] [Abstract][Full Text] [Related]
2. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.
Bennett LL; Allan PW; Noker PE; Rose LM; Niwas S; Montgomery JA; Erion MD
J Pharmacol Exp Ther; 1993 Aug; 266(2):707-14. PubMed ID: 8355201
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of 2'-deoxyguanosine cytotoxicity by a novel inhibitor of purine nucleoside phosphorylase, 8-amino-9-benzylguanine.
Shewach DS; Chern JW; Pillote KE; Townsend LB; Daddona PE
Cancer Res; 1986 Feb; 46(2):519-23. PubMed ID: 3079664
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
5. Functional and mechanistic studies on the toxicity of deoxyguanosine for the in vitro proliferation and differentiation of human peripheral blood B lymphocytes.
Scharenberg JG; Spaapen LJ; Rijkers GT; Duran M; Staal GE; Zegers BJ
Eur J Immunol; 1986 Apr; 16(4):381-7. PubMed ID: 3084280
[TBL] [Abstract][Full Text] [Related]
6. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
[TBL] [Abstract][Full Text] [Related]
8. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
9. Effects of guanine ribonucleotide accumulation on the metabolism and cell cycle of human lymphoid cells.
Sidi Y; Hudson JL; Mitchell BS
Cancer Res; 1985 Oct; 45(10):4940-5. PubMed ID: 2411392
[TBL] [Abstract][Full Text] [Related]
10. The effect of deoxyguanosine on human lymphocyte function. II. Analysis of the interference with B lymphocyte differentiation in vitro.
Spaapen LJ; Rijkers GT; Staal GE; Rijksen G; Duran M; Stoop JW; Zegers BJ
J Immunol; 1984 May; 132(5):2318-23. PubMed ID: 6425400
[TBL] [Abstract][Full Text] [Related]
11. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
12. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells.
Posmantur R; Wang KK; Nath R; Gilbertsen RB
Immunopharmacology; 1997 Oct; 37(2-3):231-44. PubMed ID: 9403342
[TBL] [Abstract][Full Text] [Related]
13. Low dose of deoxyguanosine increases IL-2 receptors of IL-2-dependent cultured T cells.
Noma T; Klein B; Yata J; Serrou B
Immunology; 1984 Jun; 52(2):247-52. PubMed ID: 6610631
[TBL] [Abstract][Full Text] [Related]
14. Effects of purine nucleoside phosphorylase deficiency on thymocyte development.
Papinazath T; Min W; Sujiththa S; Cohen A; Ackerley C; Roifman CM; Grunebaum E
J Allergy Clin Immunol; 2011 Oct; 128(4):854-863.e1. PubMed ID: 21868080
[TBL] [Abstract][Full Text] [Related]
15. Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.
Gilbertsen RB; Scott ME; Dong MK; Kossarek LM; Bennett MK; Schrier DJ; Sircar JC
Agents Actions; 1987 Aug; 21(3-4):272-4. PubMed ID: 3120507
[TBL] [Abstract][Full Text] [Related]
16. Drug evaluation: forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor.
Galmarini CM
IDrugs; 2006 Oct; 9(10):712-22. PubMed ID: 17016779
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of deoxyguanosine by B and T lymphocytes: evidence against selective trapping of deoxyguanosine by T lymphocytes in purine nucleoside phosphorylase deficiency.
North ME; Newton CA; Webster AD
Clin Exp Immunol; 1980 Dec; 42(3):523-9. PubMed ID: 6783354
[TBL] [Abstract][Full Text] [Related]
18. Different pathways for deoxyguanosine toxicity in T-lymphocytes of various developmental stages.
Scharenberg JG; Rijkers GT; Spaapen LJ; Toebes EA; Rijksen G; Duran M; Staal GE; Zegers BJ
Int J Immunopharmacol; 1988; 10(6):675-86. PubMed ID: 2974022
[TBL] [Abstract][Full Text] [Related]
19. The biochemical and pharmacological activity of 9-benzyl-9-deazaguanine, a potent purine nucleoside phosphorylase (PNP) inhibitor.
Kimble E; Hadala J; Ludewig R; Peters P; Greenberg G; Xiao G; Guida W; McQuire L; Simon P
Inflamm Res; 1995 Aug; 44 Suppl 2():S181-2. PubMed ID: 8548387
[No Abstract] [Full Text] [Related]
20. Antiproliferative activity of purine nucleoside phosphorylase multisubstrate analogue inhibitors containing difluoromethylene phosphonic acid against leukaemia and lymphoma cells.
Glavas-Obrovac L; Suver M; Hikishima S; Hashimoto M; Yokomatsu T; Magnowska L; Bzowska A
Chem Biol Drug Des; 2010 Apr; 75(4):392-9. PubMed ID: 20102369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
